Zivo Bioscience, Inc.
Bioactive molecules and nutritional compounds derived from proprietary algal strains
- Sector
- Biotech
- Headquarters
- Bloomfield Hills, MI
- Founded
- 2023
- Latest Form D
- $4M, Jul 2023
- Total capital
- $9.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $9.1M
- 20 Form D · last Jul 2023
- 39 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2019
- Rank in peer group#213 of 1462
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 20th filing$4M
- Offering registeredForm D · SEC · 19th filing$5M
- Private capital raisedForm D · SEC · 18th filing$1.3M
- Private capital raisedForm D · SEC · 17th filing$100K
- Private capital raisedForm D · SEC · 16th filing$250K
- Private capital raisedForm D · SEC · 15th filing$375K
- Private capital raisedForm D · SEC · 14th filing$132K
- Private capital raisedForm D · SEC · 13th filing$325K
- Private capital raisedForm D · SEC · 12th filing$35K
- Private capital raisedForm D · SEC · 11th filing$50K
- Private capital raisedForm D · SEC · 10th filing$140K
- Private capital raisedForm D · SEC · 9th filing$63K
- Private capital raisedForm D · SEC · 8th filing$63K
- Private capital raisedForm D · SEC · 7th filing$300K
- Private capital raisedForm D · SEC · 6th filing$600K
- Private capital raisedForm D · SEC · 5th filing$278K
- Private capital raisedForm D · SEC · 4th filing$100K
- Private capital raisedForm D · SEC · 3rd filing$113K
- Private capital raisedForm D · SEC · 2nd filing$675K
- Private capital raisedForm D · SEC · 1st filing$205K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1462 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Allison A. CornellDirectorNamed in SEC Form D filings
- ANDREW DAHLExecutive OfficerNamed in SEC Form D filings
- CHRISTOPHE MAGGIOREDirectorNamed in SEC Form D filings
- Christopher D. MaggioreDirectorNamed in SEC Form D filings
- JOHN PAYNEDirectorNamed in SEC Form D filings
- Keith R. MarchiandoExecutive OfficerNamed in SEC Form D filings
Show all 9 people
- NOLA MASTERSONDirectorNamed in SEC Form D filings
- Philip Marshall Rice IIExecutive Officer, DirectorNamed in SEC Form D filings
- ROBERT RONDEAUDirectorNamed in SEC Form D filings
Patents
- Immune Priming To Accelerate/enhance Immune Response Through Administration Of Natural Immune Modulatorgranted
- Enhancement Of Vaccine Efficacy Via Biomass And/or Related Material In Animal Drink And Feedapplication
- Algoriphagus Sp, Bosea Sp, Brevundimonas Sp, Desulfovibrio Sp, Microbacterium Sp, Sphingomonas Sp, And Variovorax Sp For Use In Disease Prevention And Treatmentapplication
- Enhancement Of Vaccine Efficacy Via Biomass And/or Related Material In Animal Drink And Feedgranted
- Gram-negative Bacteria For Use In The Prevention And Treatment Of Disease In Poultryapplication
- Agents And Method For Improving Gut Healthapplication
- Algal Feed Ingredient For Controlling The Effects Of Coccidiosis And Necrotic Enteritis In Poultryapplication
- Use Of Variovorax Microbes As An Alternative Treatment For Coccidiosisapplication
- Algoriphagus Sp, Bosea Sp, Brevundimonas Sp, Desulfovibrio Sp, Microbacterium Sp, Sphingomonas Sp, And Variovorax Sp For Use In Disease Prevention And Treatmentapplication
- Immune Priming To Accelerate/enhance Immune Response Through Administration Of Natural Immune Modulatorapplication
- Nutritional Support For Animals Via Administration Of An Algal Derived Supplementgranted
- Use Of TLR4 Modulator In The Treatment Of Coccidiosisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.